CURRICULUM VITAE

Roger D. Beyer M.D., M.A., F.A.C.O.G., C.P.I.

Women's Health Care Specialists, PC/ Beyer Research • 7110 Stadium Drive • Kalamazoo, MI 49009 •
(269) 372-7600 • Fax (269) 372-7604 • E-mail: rogerbeyermd@gmail.com

EDUCATION

1979 – 1983	Residency Program, Obstetrics & Gynecology, Barnes Hospital and St. Louis Hospital, St. Louis, MO.
1979	M.D., Case Western Reserve University, Cleveland, OH.
1972 – 1979	M.D. Ph.D. Pharmacology Program, Case Western Reserve University, Cleveland, OH.
1972	M.A. Genetics, Western Michigan University, Kalamazoo, MI.
1970	B.S. Biology, Western Michigan University, Kalamazoo, MI.

CERTIFICATIONS

2006	*Certified Physician Investigator, Association of Clinical Research Professionals*
1985	*Fellow, Board Certified by the American Board of Obstetrics & Gynecology, American College of Obstetrics & Gynecology*

CURRENT LICENSURE

Michigan, Wisconsin, and Missouri

PROFESSIONAL EXPERIENCE

2000-present — *Beyer Research, Kalamazoo, MI.*
Principal Investigator over multiple multi-therapeutic drug, device and surgical trials, Phases II-IV. No history of FDA Audit. GDUFA Self-Identified.

1984-present — *Women's Healthcare Specialists, P.C., Kalamazoo, MI.*
Solo comprehensive obstetrics & gynecology practice.
Extensive training in complex vaginal surgery.
Routinely perform repairs for total procidentia, vaginal prolapse and cystocele/rectocele/enterocele repair using transvaginal and intra-abdominal approaches.
Perform extensive operative laparoscopic procedures and urogynecologic procedures.

TEACHING AFFILIATIONS

2000 - Adjunct Faculty, Western Michigan University, Kalamazoo, MI

COMMITTEE ASSIGNMENTS

1997-present	Michigan Maternal Mortality Surveillance (MMMS), Medical Review Committee, Division of Michigan Department of Public Health
1997-2009	Committee on Maternal and Perinatal Health, Michigan State Medical Society

PROFESSIONAL SOCIETIES

American Association of Gynecologic Laparoscopists
American College of Obstetrics and Gynecology – Fellow
American Medical Association
American Urogynecologic Society
Association of Clinical Research Professionals
International Urogynecological Association
International Continence Society
International Society for Study of Women's Sexual Health
Michigan State Medical Society
Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction
Van Buren County Medical Society

PRINCIPAL INVESTIGATOR EXPERIENCE BY THERAPEUTIC AREA

Women's Health Care/Gynecology

A randomized, Investigator-blind, placebo-controlled, parallel design, multiple-site study comparing Sun Pharmaceutical Industries, LTD Estradiol vaginal tablets with Vagifem® (Estradiol) vaginal tablets (Novo Nordisk) in the treatment of **atrophic vaginitis.**

A randomized, multicenter, double-blind, vehicle-controlled study to evaluate the safety and efficacy of WC3011 in **postmenopausal women**, Study PR-05812.

A multicenter, open-label extension study to evaluate the long-term safety and efficacy of WC3011 (estradiol vaginal gel) in the treatment of symptoms of **vulvovaginal atrophy** in postmenopausal women.

A randomized, blinded, multicenter study to evaluate the efficacy and safety of Varisolve™ Polidocanol Endovenous Microfoam (PEM) 0.5%, 1.0% and 2.0% compared to vehicle for the treatment of **saphenofemoral junction (SFJ)** incompetence.

A randomized, double-blind, vehicle-controlled study of the safety and efficacy of WC3011 (estradiol vaginal gel) in the treatment of symptoms of **vulvovaginal atrophy** in postmenopausal women.

Data collection of the **functional anterior vaginal wall length** for product development research of pelvic floor repair system.

DHEA against **vaginal atrophy** – safety study of 12 months.

DHEA against **vaginal atrophy** (placebo-controlled, double-blind and randomized Phase 3 study of 3-month intravaginal DHEA).

A Phase 3 multicenter, randomized, double-blind, placebo-controlled study to investigate the safety and efficacy of gabapentin extended release (G-ER) tablets in the treatment of **vasomotor symptoms in postmenopausal women.**

A randomized open-label study to evaluate the safety and efficacy of denosumab and ibandronate in **postmenopausal women** sub-optimally treated with daily or weekly bisphosphonates.

A randomized, double blind, placebo-controlled, parallel-group study evaluating the safety and efficacy of clindamycin/butoconazole vaginal cream in the treatment of **mixed bacterial vaginosis/vulvovaginal candidiasis infections.**

Phase 3 multicenter, randomized, double blind, placebo-controlled study to investigate the safety and efficacy of gabapentin extended release (ER) tablets in the treatment of **vasomotor symptoms in postmenopausal women.**

A multicenter, open label, extension study to evaluate the safety 1.3 G oral doses of oral tranexamic acid TID during menstruation for the treatment of **menorrhagia.**

A multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of oral Angeliq (drospirenone 0.5 mg/17ß-estradiol 0.5 mg, drospirenone 0.25 mg/17ß-estradiol 0.5 mg, and 17ß-estradiol 0.3 mg) for the relief of moderate to severe **vasomotor symptoms in postmenopausal women** over a treatment period of 12 weeks.

A Phase 2, 18-week, double-blind, placebo-controlled, multicenter study evaluating the safety and efficacy of lidocaine/diphenhydramine combination cream compared with lidocaine and placebo creams in the treatment of **vulvar vestibulitis syndrome.**

A Phase II, randomized, double blind, active-controlled study to assess the safety and efficacy of NBI-56418 in subjects with **endometriosis.**

A Phase 2, 16 week, multicenter, randomized, double blind placebo controlled, parallel group proof of concept study evaluating the efficacy and safety of Tanezumab for the treatment of pain associated with **endometriosis.**

Multicenter, double-blind, randomized, placebo-controlled study to determine the lowest effective dose of progestin/estradiol for the relief of moderate to severe **vasomotor symptoms in postmenopausal women.**

Multicenter, double blind randomized, placebo-controlled, parallel-group, multicenter study to evaluate efficacy and safety, drug study for treatment of **menorrhagia.**

A randomized, placebo-controlled, Phase II study of multiple dosing regimes of Intravaginally Administered 851B Gel for the Treatment of **Cervical High Risk HPV Infection.**

A double-blind randomized, placebo and active controlled efficacy and safety study of bazedoxifenen/conjugated estrogens combination for treatment of moderate to severe **vulvar/vaginal atrophy** in postmenopausal women.

Women's Health Care/Gynecology/Contraception

Opel-label study of the safety and efficacy of a low dose **oral contraceptive** chewable tablet containing Norethindrone Acetate and Ethinyl Estradiol, Study PR-01613.1.

An open-label, randomized, parallel group, phase 3 study of the contraceptive efficacy and safety of test article **transdermal contraceptive** delivery system (TCDS) in comparison to a low-dose oral contraceptive containing 0.02 mg ethinyl estradiol and 0.1 mg levenorgestrel in a 21-day regimen.

An open-label, randomized, parallel group. Phase 3 study of the contraceptive efficacy and safety of Agile **transdermal contraceptive** delivery system (TCDS) in comparison to a low-dose oral contraceptive containing 0.02 mg Ethinyl estradiol and 0.1 mg levonorgestral in a 21-day regimen.

An open label study to evaluate the **contraceptive** efficacy and safety of norethindrone acetate transdermal delivery system.

Multi-center, double-blind, double-dummy, randomized, parallel-group study to evaluate cycle control, bleeding pattern, blood pressure, lipid and carbohydrate metabolism of the **transdermal contraceptive patch** (material no. 80876395 / 2.1 mg gestodene and 0.55 mg Ethinyl estradiol) vs. an oral comparator containing 20 µg Ethinyl estradiol and 100 µg levonorgestrel in a 21-day regimen for 7 cycles in 400 women.

Multicenter, open label, single-arm study to assess the efficacy and safety of the **oral contraceptive** test article in a flexible extended regimen for one year.

A multicenter, open-label, single-arm study to assess the efficacy and safety of the **oral contraceptive** SH T00186D (0.02 mg Ethinyl estradiol as betadex clathrate and 3 mg drospirenone) in a flexible extended regimen in 1356 healthy females for 1 year.

A multicenter, open-label, three-arm, active-controlled study to assess the efficacy and safety of the **oral contraceptive** SH T00186D (0.02 mg ethinyl estradiol as betadex clathrate and 3 mg drospirenone) in two flexible extended regimens and a conventional regimen of Yaz in 1756 healthy females for 1 year.

Multi-center, open label, randomized study to assess the safety and contraceptive efficacy of two doses of (in vitro 12 µg/24 h and 16 µg/24 h) of the ultra-low dose levonorgestrel **intrauterine systems** (LCS) for a maximum of 3 years in women 18 to 35 years of age.

Multicenter, prospective surveillance study to monitor and measure the risks of various **oral contraceptives.**

An evaluation of consumer acceptance and satisfaction with the use of a **vaginal ring delivery system.**

Sexual Medicine

A randomized, multicenter, double-blind, vehicle-controlled study to evaluate the safety and efficacy of WC3011 in postmenopausal women with **dyspareunia**, Study PR-08112.

A Phase 3, multi-center extension study to assess persistence of benefit of LibiGel® for the treatment of **hypoactive sexual desire disorder** in surgically menopausal women.

A twenty-four week, randomized, double-blind, placebo controlled, safety and efficacy trial of flibanserin, with up-titration, 100 milligrams administered orally once daily in naturally postmenopausal women with **hypoactive sexual desire disorder** in North America.

A Phase III, randomized, double-blind, placebo-controlled, multi-center study of the long term safety and efficacy of Libigel® for the treatment of **hypoactive sexual desire disorder** in postmenopausal women.

A Phase III, randomized, double-blind, placebo-controlled, multi-center study of the safety and efficacy of Libigel® for the treatment of **hypoactive sexual desire disorder** in surgically menopausal women.

A randomized, double-blind, placebo-controlled, multicenter, 52-week study to evaluate the endometrial safety of transdermal testosterone in naturally menopausal women with **hypoactive sexual desire disorder.**

Urology

A randomized, double-blind, multi-centre study to evaluate the efficacy and safety of adding Mirabegron to Solifenacin in **incontinent OAB** subjects who have received Solifenacin for 4 weeks and warrant addition relief for their OAB symptoms.

A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study to evaluate the efficacy, safety, and tolerability of dexmecamylamine in the treatment of subjects with **overactive bladder (OAB).**

A double-blind, randomized, placebo-controlled study investigating the impact burden of **nocturia** using the nocturia impact diary.

A 14-week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in **overactive bladder** patients with sub-optimal response tolterterodine 4 mg ER.

A multi-centre, randomised, double-blind, placebo-controlled, parallel-group trial with an open-label extension to demonstrate the efficacy and safety of desmopressin orally disintegrating tablets for the treatment of **nocturia** in adult males.

A multi-center, double-blind, placebo-controlled trial of Sanctura XR 60 mg daily in female **OAB** patients on multiple concomitant medications refractory to Detrol LA 4 mg daily.

A multi-centre, randomized, double-blind, placebo-controlled, parallel-group trial to demonstrate the efficacy and safety of desmopressin orally disintegrating tablet for the treatment of **nocturia** in adult females.

A multi-centre, randomised, double-blind, placebo-controlled, parallel-group trial to demonstrate the efficacy and safety of desmopressin orally disintegrating tablet for the treatment of **nocturia** in adult females.

Device to treat **urinary incontinence** – effectiveness, tolerability, and satisfaction.

A 12-week, randomized, double blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of fesoterodine flexible dose regimen in vulnerable elderly patients with **overactive bladder.**

Randomized, double blind, placebo-controlled, parallel-group, multi-center study with a double-blind extension investigating the efficacy and safety for the treatment of **nocturia** in adults.

A randomized, double-blind, placebo controlled, parallel group multi-center study investigating the efficacy and safety of a fast-dissolving ("melt") formulation of desmopressin in the treatment of **nocturia** in adults

Prospective study to evaluate the effectiveness of the treatment for female **stress urinary incontinence** in women with suboptimal response to surgical treatment.

A 12-week, randomized, double blind, placebo-controlled, parallel-group, multicenter trial to evaluate the efficacy and safety of a fesoterodine flexible dose regimen in patients with **overactive bladder.**

A prospective study to evaluate the effectiveness of the Renessa® Treatment for female **stress urinary incontinence** in women with suboptimal response to surgical treatment.

Open-labeled, multicenter, randomized long-term prospective study of transdermal medication for **overactive bladder** in a community-based population.

Neurology/Pain Management

A study to assess efficacy over placebo and speed of onset **of pain relief of New Pandol** Extra as compared to Ibuprofen in **episodic tension type headache.**

A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of Elagolix in subjects with moderate to severe **endometriosis-associated pain.**

A phase 3B multicenter, double-blind, randomized withdrawal efficacy and safety study of pregabalin in the treatment of patients with inadequately **treated painful diabetic peripheral neuropathy.**

Phase 2, 16 week, multicenter, randomized, double-blind placebo-controlled, parallel group proof of concept study evaluating the efficacy and safety of tanezumab for the treatment of **pain associated with endometriosis.**

A randomized, double blind, placebo-controlled parallel group evaluation of the efficacy and tolerability of two different doses of Elmiron® for the treatment of **interstitial cystitis.**

A Phase 2b, randomized, double-blind, placebo-controlled, dose ranging study evaluating the efficacy and safety of tanezumab for the treatment of moderate to severe pain associated with **interstitial cystitis/painful bladder syndrome** (IC/PBS).

A four-week, double-blind, placebo-controlled, randomized, multicenter study evaluating the safety and efficacy of AF-219 in female subjects with **interstitial cystitis/bladder pain syndrome.**

A long-term safety study of a combination product containing sumatriptan succinate and naproxen sodium for the treatment of **migraine in adolescents.**

Multi-center, parallel group, double-blind, placebo-controlled, dose ranging study of the efficacy and tolerability of tonabersat in the prophylaxis of **migraine headache** and open label extension.

Sub-I for multicenter, double blind, placebo-controlled, randomized study of a pain medication for **post-operative pain following vaginal hysterectomy.**

Multicenter prospective study using the MIDAS questionnaire to assess the effects of using the Headache Care for Practicing Clinician guidelines for **migraine** treatment.

Cardiology

A multicenter, randomized, double-blind, placebo-controlled, 8-week study to evaluate the safety and efficacy of nebivolol and valsartan given as a fixed-dose combination in patients with stage 1 or 2 essential **hypertension.**

A multicenter, open-label, single-arm, free tablet combination, long-term study to evaluate the safety of nebivolol in combination with valsartan in patients with stage 1 or stage 2 essential **hypertension.**

A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of the efficacy and safety of nebivolol in younger patients (18 - 54 years) who have stage 1 or 2 essential **hypertension.**

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the effect of 5 mg or 20 mg nebivolol once daily on blood pressure in patients with systolic stage 2 **hypertension.**

A randomized, double blind, parallel group study evaluating the efficacy and safety of co-administration of a triple combination therapy of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide in subjects with **hypertension.**

Blood pressure and metabolic effects of nebivolol compared with hydrochlorothiazide and placebo in **hypertensive** patients with impaired glucose tolerance or impaired fasting glucose.

Tolerability of nebivolol compared to metoprolol ER in patients with mild-moderate **hypertension** on hydrochlorothiazide.

A double-blind, randomized, active-control study to evaluate effects of Drospirenone/Estradiol (Angelique©) and Medroxyprogesterone Acetate/Conjugated Equine Estrogen (Prempro™) on blood pressure and sodium sensitivity in **postmenopausal women with prehypertension.**

Gastroenterology

A multicenter, randomized, double-blind, placebo-controlled Phase 3 study to evaluate the efficacy and safety of CB-5945 for the treatment of **opioid-induced constipation** in adults taking opioid therapy for chronic non-cancer pain.

A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to evaluate the long-term safety and tolerability of CB-5945 for the treatment of **opioid-induced constipation** in adults taking opioid therapy for chronic non-cancer pain

A randomized, double-blind, double-dummy, placebo-controlled, parallel-group, multicenter study to evaluate the clinical equivalence of Lubiprostone 24mcg capsules (Dr. Reddy's Laboratories Ltd.) with AMITIZA (Lubiprostone) 24 mcg capsules (Sucampo Pharmaceuticals, Inc.) in the treatment of **chronic idiopathic constipation.**

A randomized, double-blind, placebo-controlled, multicenter, Phase II study to evaluate the efficacy and safety of 12 weeks of treatment with two different doses of oral CNDO 201 Trichuris Suis Ova Suspension (TSO) as compared to placebo, followed by a 12 week open-label treatment period with TSO, in patients with moderately to severely active **Crohn's disease.**

A Phase 2, multi-center, randomized, double-blind, placebo-controlled, multiple-dose study to determine the safety and efficacy of orally administered LX1033 in subjects with **diarrhea-predominant irritable bowel syndrome (IBS-D).**

A study to assess repeat treatment efficacy and safety of Rifaximin 550 mg TID in subjects with **irritable bowel syndrome with diarrhea (IBS-D).**

A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy, safety, and tolerability of JNJ-27018966 in the treatment of patients with diarrhea-prominent **irritable bowel syndrome.**

A phase 2, multi-center, randomized, double-blind, placebo-controlled, multiple-dose study to determine the safety and efficacy of orally administered LX1033 in subjects with diarrhea-predominant **irritable bowel syndrome (IBS-D).**

A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of NKTR-118 in relieving **opioid-induced constipation** (OIC) in patients with cancer-related pain.

Phase 2 randomized, double-blind, placebo-controlled, repeat-dose study to evaluate the safety, tolerability, and efficacy of ALKS 37 in subjects with **opioid-induced constipation**.

A randomized, 12-week double-blind, placebo-controlled, repeat-dose, oral, dose-ranging study to assess the safety and efficacy of plecanatide in patients with **chronic idiopathic constipation**.

An open-label 52-week study to assess the long-term safety of NKTR-118 in **opioid-induced constipation** (OIC) in patients with non-cancer-related pain.

A randomized, double-blind, placebo-controlled study to assess the safety and efficacy of RDX5791 for the treatment of constipation-predominant **irritable bowel syndrome (IBS-C).**

A multicenter, 1-week, double-blind, randomized, placebo-controlled trial comparing the Lubiprostone 24-ug Capsule Formulation (Sucampo Pharma Americas, Inc and Takeda Pharmaceuticals America, Inc) in subjects with **chronic idiopathic constipation.**

A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of oral methylnaltrexone (OM) for the treatment of **opioid-induced constipation** (OIC) in subjects with chronic, non-malignant pain.

A randomized, double-blind, placebo-controlled, parallel group, dose ranging, multicenter study to evaluate the efficacy, safety, and tolerability of JNJ-27018966 in the treatment of patients with **irritable bowel syndrome with diarrhea.**

A 12-week, randomized, double-blind, placebo-controlled study of asimadoline in subjects with **diarrhea-predominant irritable bowel syndrome.**

A multicenter, open-labeled study of the long-term safety and efficacy of lubiprostone in patients with **opioid-induced bowel dysfunction.**

A Phase 3, randomized, double blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin 550 mg TID in the treatment of subjects with non-constipation **irritable bowel syndrome.**

An open-label study to evaluate the long-term safety of subcutaneous MOA-728 for treatment of **opioid-induced constipation** in subjects with non-malignant pain.

A multicenter, randomized, double-blind, placebo-controlled, parallel-group study of subcutaneous MOA-728 for the treatment of **opioid induced constipation** in subjects with **chronic non-malignant pain.**

A randomized, double blind, placebo-controlled study to evaluate the safety and effectiveness of DDP733 in female patients with **irritable bowel syndrome with constipation.**

A multicenter, randomized, placebo-controlled, double-blinded study of the efficacy and safety of lubiprostone in patients with **opioid-induced bowel dysfunction.**

Respiratory

A 26 week, randomized, double-blind, parallel-group, active controlled, multicenter, multinational safety study evaluating the risk of serious asthma-related events during treatment with Symbicort®, a fixed combination of inhaled corticosteroid (ICS) (budesonide) and a long acting β_2-agonist (LABA) (formoterol) as compared to treatment with ICS (budesonide) alone in adult and adolescent (>12 years of age) patients with **asthma.**

A 52-week, randomized, double-blind, parallel-group, multi-centre, Phase IIIB study comparing the long term safety of SYMBICORT® pMDI 160/4.5 ug x 2 actuations twice daily to budesonide HFA pMDI 160 ug x 2 actuations twice daily in adult and adolescent (>12 years) **African American subjects with asthma.**

A randomized, open-label, multicenter trial of the safety and effectiveness of oral telithromycin (Ketek®) and amoxicillin/clavulanic acid (Augmentin®) in outpatients with **respiratory tract infections** in usual care settings.

Open-labeled, multicenter non-comparative clinical study of an oral fluoroquinolone in the treatment of community-acquired **respiratory tract infection.**

Endocrinology

A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0100 in two titration regimens on top of metformin in patients with **type 2 diabetes** not adequately controlled with metformin.

A randomized, double-blind, placebo-controlled, parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0100 on top of metformin in patients with **type 2 diabetes** not adequately controlled with metformin.

A randomized, double-blind, double-dummy, 2-arm parallel-group, multicenter 24-week study comparing the efficacy and safety of test article to sitagliptin as add-on to metformin in **obese type 2 diabetic patients** younger than 50 and not adequately controlled with metformin.

A randomized, double-blind, placebo-controlled, dose-ranging, exploratory, 28-day study to examine the effects of AR9281 on blood pressure and glucose tolerance in patients with mild to moderate **hypertension and impaired glucose tolerance.**

A multicenter, double blind, placebo-controlled study to determine the efficacy and safety of the combination of SYR-322 and pioglitazone HCL (Actos®) in subjects with **type 2 diabetes.**

Surgical

Prospective, multicenter study to assess an anterior synthetic mesh repair system with **apical prolapse.**

Prospective, multicenter study to assess the AMS pelvic floor repair system devices for **prolapse repair.**

Multicenter prospective study reviewing information related to patient outcomes with the use of synthetic devices for posterior **prolapse repair** and vaginal vault suspension system.

Multicenter prospective study to document baseline, procedural and outcome variables associated with a synthetic mesh device **anterior prolapse repair** system.

A multi-center study to assess the Perigee™ transobturator **anterior prolapse repair** system with IntePro™ large pore polypropylene.

Metabolic/Orthopedic

A double-blind randomized, placebo and active-controlled efficacy and safety study of the effects of bazedoxifene/conjugated estrogens combination on **endometrial hyperplasia and prevention of osteoporosis** in postmenopausal women.

Open-label, randomized, parallel-group study comparing two medications in subjects with **iron-deficiency anemia.**

Multicenter, double-blind randomized, placebo vs. active, controlled efficacy and safety, drug study for prevention of **osteoporosis** in postmenopausal women.

A double-blind, randomized, placebo and active controlled efficacy and safety study of bazedoxifene/conjugated estrogens combinations for prevention of endometrial hyperplasia and prevention of **osteoporosis** in postmenopausal women.

Multicenter, prospective surveillance study of patient outcomes comparing two drug treatments for **osteoporosis** vs. vitamin D and/or calcium.

UNPUBLISHED RESEARCH

1989	"Does the Effect of Acetic Acid Spraying as Well as a Pap Smear Increase the Find Rate of CIN?"

UNIVERSITY RESEARCH

1974 - 1978	Research Assistant, Hematology, Case Western Reserve University
1972 - 1974	Research Assistant, Environmental Health Program, Department of Pharmacology, Case Western Reserve University
1970 - 1972	Research Assistant, Genetics, Western Michigan University
1971	Research Assistant, Organic Chemistry, Western Michigan University

MEDICAL ADVISOR

Takeda Pharmaceuticals
Speaker
Deerfield, IL

American Medical System
Consultant and Trainer
Division of Urology and Pelvic Health
Minnetonka, MN

PUBLICATIONS

Lukban JC, **Beyer RD**, Moore, RD, Incidence of Extrusion Following Type I Polypropylene Mesh "Kit" Repairs in the Correction of Pelvic Organ Prolapse, Obstet Gyn Int, Volume 2012, Article ID 354897.

Moore RD, **Beyer RD**, Jacoby K, Freedman SJ, McGammon KA, Gambia MT. Prospective Multicenter Trial Assessing Type I, Polypropylene Mesh Placed Via Transobturator Route for the Treatment of Anterior Vaginal Prolapse with 2 Year Follow-Up. Int Urogyn J, (2010) 21:545-552.

Davila GW, Flaherty JF, Lukban JC, **Beyer R**, Patel M, Moore RD, Retrospective Analysis of Efficacy and Safety of Perigee™ and Apogee™ in Patients Undergoing Repair for Pelvic Organ Prolapse, Int Urogyn J, (2006) 17 (Suppl 2):S256.

Beyer RD. Transobturator Suburethral Tape Procedure For the Management of Urinary Stress Urinary Incontinence in the Gynecologic Patient. Southwest Michigan Medical Journal 2004(July);1(2):20-24.

Ficsor, G, Fuller S, Jeromin J, **Beyer RD**, Janca F. Enhancing Cervical Cancer Detection Using Nucleic Acid Hybridization and Acetic Acid Tests. Nurse Pract 1990(July); 15(7):26-30.

Anton AH, Serrano A, **Beyer RD**, Lavappa KS. Tetrahydrocannabinoid sesame oil and biogenic amines: A preliminary report. Life Sciences 1974(May);14(9):1741-46.

Leash AM, **Beyer RD**, Wiber RG. Self-mutilation following Innovar-Vet injection in the guinea pig. Laboratory Animal Science 1973(Oct);23(5):720-21.

Trimitsis G, Tuncay A, **Beyer RD**, Ketterman KJ. *a,a'*-Dimetalations of Dimethylarenes with Organosodium Reagents. The Catalytic Effect of Certain Tertiary Amines. J Org Chem 1973; 38(8):1491-92.

Lavappa KS, Fu MM, Sing M, **Beyer RD**, Epstein SS. Banding patterns of chromosomes in bone marrow cells of the Chinese hamster as revealed by acetic-saline-Giemsa, urea and trypsin techniques. Laboratory Animal Science 1973:23(4)546-50.

Beyer RD. The Organ-Specific Mammalian Host-Mediated Microbial Mutagen Assay (OSHMA). Masters Thesis, Western Michigan University, December 1972.

Trimitis GB, Tuncay A, **Beyer RD**. Metalations of dimethylarenes with organosodium reagents. Catalytic effect of certain tertiary amines. J Am Chem Soc 1972(March);94(6):2152-53.

Ficsor G, **Beyer R**, Janca FC, Zimmer DM. An organ specific host-mediated microbial assay to detect chemical mutagens in vivo: demonstration of mutagenic action in rat testes following strepozotocin treatment. Mutation Res 1971; 13:283-287.

ABSTRACTS/ POSTERS

Beyer RD, Freeman E, Adomako T, Reductions in Menstrual Blood Loss for Women with Heavy Menstrual Bleeding Treated with Tranexamic Acid According to Body Mass Index, 15th Annual Women's HealthCare Conference, Orlando, Florida, October 10-13, 2012.

Stanford EJ, Moore RD, Roovers JW, Courtieu C, **Beyer R**, Lukban JC, Bataller E, Sutherland SE, A Prospective Multi-center Clinical Trial Evaluating Elevate Anterior and Apical in the Treatment of Pelvic Organ Prolapse: Two-Year Follow-up, 37th Annual IUGA Meeting, Brisbane, Australia, 4-8 September 2012 (Int Urogyn J, (2012) 23 (Suppl 2): S128).

Stanford EJ, Moore RD, Roovers JR, Courtieu C, **Beyer R**, Lukban JC, Bataller E, Sutherland SE, Quality of Life Assessment Two Years Post Surgical Treatment for Pelvic Organ Prolapse Using Transvaginal Mesh, 37th Annual IUGA Meeting, Brisbane, Australia, 4-8 September 2012 (Int Urogyn J (2012) 23 (Suppl 2): S87).

Lukban JC, VanDrie D, Nguyen JNK, Zylsra S, **Beyer R**, Two-Year Follow-up of Elevate Apical and Posterior with InteXen LP: A Single-Incision Approach To Treat Apical and Posterior Vaginal Wall Prolapse, 40th AAGL Global Congress of Minimally Invasive Gynecology, Hollywood, Florida, November 6-10, 2011 (J Min Invasive Gyn, Nov/Dec 2011, 18(Supp) (6) S166.

Standford EJ, Moore RD, **Beyer R**, Roovers J, Giudice T, Lukban JC, Bataller E, Sutherland SE, Safety and Efficacy of Elevate Anterior/Apical in Surgical Treatment of Pelvic Organ Prolapse, 32nd Annual Scientific Meeting AUGS, Providence, Rhode Island, September 13-17, 2011 (Female Pelv Med & Reconst Surgery, Sept/Oct 2011, 17(Supp) (5) S116.

Lukban JC, **Beyer R**, Erickson T, Roovers J, Zylstra S, Patel M, Moore RD, Long Term Results of Elevate Apical and Posterior for Vaginal Wall Prolapse Repair, 32nd Annual Scientific Meeting AUGS, Providence, Rhode Island, September 13-17, 2011 (Female Pelv Med & Reconst Surgery, Sept/Oct 2011, 17(Supp) (5) S118.

Lukban JC, Moore RD, VanDrie DM, **Beyer RD**, Elevate Apical and Posterior (Elevate A&P) in Patients with Posterior and/or Apical Vaginal Wall Prolapse: One-Year Follow-Up, 39th Annual Congress of Minimally Invasive Gynecology, Las Vegas, Nevada, November 8-12, 2010 (J Min Invasive Gyn (2010) 17 (Supp) 17(6) S63.

J Lukban, D VanDrie, **R Beyer**, T Erickson, R Moore, J Nguyen, M Patel, A Prospective Multicenter Study Evaluating Elevate Apical and Posterior (A&P) for Treatment of Posterior and/or Apical Vaginal Wall Prolapse: One-Year Follow-Up, 31st Annual Meeting of AUGS, Long Beach, California, September 29-October 2, 2010 (J Pelv Med & Surg, Sept/Oct 2010, 16 (Supp) (5) S118.

Lukban J, Roovers, J, Moore RD, Patel M, Courtieu C, Mayne C, Flaherty J, Liedl B, Lange R, **Beyer R**, A Prospective Multicenter Study Evaluating Elevate Apical and Posterior for Treatment of Posterior and/or Apical Vaginal Wall Prolapse: Twelve-Month Follow-Up, Joint Meeting of the International Continence Society and the International Urogynecological Association, Toronto, Canada, 23-27 August 2010 (Neurology and Urodynamics (2010) 29(6)1209 and (Int Urogyn J (2010) 21 (Supp 1)):S404.

Lukban J, **Beyer R**, Roovers JP, VanDrie D, Patel M, et al, A Prospective, Multi-Center Clinical Trial Evaluating Elevate Apical and Posterior (Elevate A&P) in Patients with Posterior and/or Apical Vaginal Wall Prolapse: Six-Month Follow-Up, 38th Global Congress of Minimally Invasive Gynecology, Orlando, Florida, November 15-19, 2009 (J Min Invasive Gyn (2009) 16 (Supp) 16(6) S46.

Lukban J, **Beyer R**, Roovers JP, VanDrie D, Patel M, et al, A Prospective, Multi-Center Clinical Trial Evaluating Elevate Apical and Posterior (Elevate A&P) in Patients with Posterior and/or Apical Vaginal Wall Prolapse: Six-Month Follow-Up, 38th Global Congress of Minimally Invasive Gynecology, Orlando, Florida, November 15-19, 2009 (J Min Invasive Gyn (2009) 16 (Supp) 16(6) S46).

RD Moore, **R Beyer**, et al, Prospective Multi-center Trial Assessing Type I, Polypropolene Mesh Placed Via a Transobturator Approach For Anterior Wall Prolapse With 2 Year Follow-up, 30th Annual Meeting of AUGS, Hollywood, Florida, Sept 24-26, 2009 (J Pelv Med & Surg, Sept/Oct 2009, 12(5)262).

Moore RD, **Beyer R**, Jacoby K, et al, Anterior Repair with Mesh Graft Via Transobturator Approach: With or Without Prior Repair, Scientific Poster, 34th Annual IUGA Meeting, Lago di Como, Italy, June 2009, Int. Continence Society (ICS) 39th Annual Meeting, September 2009, San Francisco, CA.

RD Moore, **R Beyer**, et al, Perigee Synthetic Study 12-month Data, 35th Annual Scientific Meeting, New Orleans, Louisiana, Mar 30-Apr 1, 2009.

Moore RD, **Beyer R**, Jacoby K, et al, A Multi-Center Trial Assessing Type 1, Polypropolene for the Treatment of Anterior Vaginal Prolapse, J Pelv Med & Surg, March/April 2009, Vol 15(2):44-45, presented at SGS 35th Annual Meeting, New Orleans, LA, April 2009.

Beyer R, Impact of Closure Technique on Extrusion Outcomes in 54 Women Treated with Type I Polypropolene Mesh for Vaginal Prolapse, Annual Meeting of the AAGL, Las Vegas, Nevada, Oct 28-Nov 1, 2008 (J Min Invasive Gyn, Nov/Dec 2008, 15(6) Supp:S14).

J Lukban, M Patel, D VanDrie, **R Beyer**, et al, A Prospective Multi-Center Clinical Trial Evaluating the Apogee System for the Treatment of Posterior Vaginal Wall and Apical Prolapse: A Sub-Analysis of Apical Extrusions with or without

Concomitant Hysterectomy, Annual Meeting of the AAGL, Las Vegas, Nevada, Oct 28-Nov 1, 2008 (J Min Invasive Gyn, Nov/Dec 2008, 15(6) Supp:S36).

Moore R, Lukban J, **Beyer R**, Incidence of Extrusion in Patients Treated with Type I Polypropolene Mesh "Kits" in Pelvic Organ Prolapse Repair, 37th Annual Meeting of the AAGL, Las Vegas, Nevada, Oct 28-Nov 1, 2008 (J Min Invasive Gyn, Nov/Dec 2008, 15(6) Supp:S140 (author inadvertently omitted)).

RD Moore, **R Beyer**, K Jacoby, S Freedman, et al, Multi-center trial evaluating the 6 and 12 month efficacy and safety of the Perigee System with IntePro, 33rd Annual IUGA Meeting, Taipei, Taiwan, September 15-17, 2008 (Int Urogyn J (2008) 19 (Suppl 1)):S29).

J Lukban, T Erickson, M Virelles, **R Beyer**, R Moore, et al, A Prospective Multi-Center Clinical Trial Evaluating the Apogee System for the Treatment of Posterior Vaginal Wall and Apical Prolapse, 33rd Annual IUGA Meeting, Taipei, Taiwan, September 15-17, 2008 (Int Urogyn J (2008) 19 (Suppl 1)):S90).

J Lukban, M Patel, D VanDrie, **R Beyer,** et al, A Prospective Multi-Center Clinical Trial Evaluating the Apogee System for the Treatment of Posterior Vaginal Wall and Apical Prolapse: A Sub-Analysis of Apical Extrusions with or without Concomitant Hysterectomy, (Poster) J Pelv Med & Surg, Jul/Aug 2008; 14(4)271.

RD Moore, **R Beyer**, et al, Anterior Repair With Mesh: with or without Prior Anterior Repair, (Poster) J Pelv Med & Surg, Jul/Aug 2008; 14(4)276, presented at AUGS, poster,28.

J Lukban, TB Erickson, M Virelles, M Patel, D VanDrie, **R Beyer**, et al, A Prospective Multi-Center Clinical Trial Evaluating the Apogee System for the Treatment of Posterior Vaginal Wall and Apical Prolapse, AUA Annual Meeting, Orlando, Florida, May 17-22, 2008 (J Urol, Apr 2008; 179(4 Suppl):448).

R Moore, **R Beyer**, et al, Anterior Prolapse Repair With Mesh: With or Without an Incontinence Repair, AUA Annual Meeting, Orlando, Florida, May 17-22, 2008.

R Moore, **R Beyer**, et al, Multi-center trial evaluating the intra-operative safety and 6 and 12-month efficacy of the Perigee System, AUA Annual Meeting, Orlando, Florida, May 17-22, 2008.

RD Moore, **R Beyer**, JR Miklos, K Jacoby, S Freedman, K McCammon, M Gambla, E Jacome, G Badlani. Prospective, Multicenter Trial Evaluating the Perigee System With Polypropylene Mesh for Cystocele Repair: Estrogenicity and Outcomes. 36th Global Congess of Minimally Invasive Gynecology (sponsored by the AAGL). Washington, D.C., November 14-17, 2007. (J Pelvic Med & Surg, 2007 Sept/Oct;13(5):255).

RD Moore, **R Beyer**, J Miklos, et al, "Prospective, Multi-Center Trial Evaluating the Perigee System with Polypropylene Mesh for Cystocele Repair: Etrogenicity and Outcomes", AUGS 28th Annual Scientific Meeting, Hollywood, FL, September 26-29, 2007 (J Pelvic Med & Surg, Vol 13, No. 5, 2007:(61)255-256).

RD Moore, JR Miklos, **R Beyer**, Prospective, multi-center trial evaluating the Perigee System with polypropylene mesh for cystocele repair, presented at the 32nd Annual Meeting. IUGA, Cancun, Mexico, June 12-17, 2007 (Intl. Urogyn J, (2007) 18 (Suppl 1):S068).

Davila GW, Flaherty JF, Lukban JC, **Beyer R**, Patel M, Moore RD, Retrospective analysis of Efficacy and Safety of Perigee and Apogee in Patients Undergoing Repair for Pelvic Organ Prolapse, 35th Annual Meeting of the AAGL, Las Vegas, Nevada, November 6-9, 2006 (J Min Invasive Gyn, Sep/Oct 2006(Supp), 13(5) S27).

Davila GW, Flaherty JF, Lukban JC, **Beyer R**, Patel M, Moore RD, Retrospective analysis of Efficacy and Safety of Perigee and Apogee in Patients Undergoing Repair for Pelvic Organ Prolapse. Poster accepted for 27th annual AUGS Scientific Meeting 2006; October 19-21, 2006; Palm Springs, California.

Davila GW, **Beyer R**, Moore, RD, et al, Restoration of Vaginal Apical and Posterior Wall Support with the Apogee System, 30th Annual Meeting of IUGA, Copenhagen, August 2005 and 35th Annual ICS Meeting, Montreal, Canada, August 2005 (Int Urogyn J 2005; 16(Supp 2): S117-118).

Ficsor G, Fuller S, Jeromin JS, **Beyer R**, Janca F, Cervical cancer risk evaluation by acetic acid, Pap, and human papilloma virus (HPV) nucleic acid hybridization tests, 92nd Annual Meeting Michigan Academy of Science, Arts and Letters, Grand Rapids, Michigan, March 17-18, 1989.

Ficsor G, Fuller S, Jeromin JS, **Beyer R**, 1988, Detection and typing of cervical human papilloma viruses with DNA RNA hybridization, 16th International Congress Genetics, Toronto, Canada.

Ficsor G, **Beyer RD**, 1975, Methodology for dosimetry of chemical mutagens in retetestis fluid of the vas deferens, Mutation Research 31:331.